Positive preliminary results announced from ongoing phase III PUNCH CD3 trial of RBX2660, a microbiome-based C. difficile treatment

Positive data reported for primary efficacy endpoint (prevention recurrent C. diff at 8 weeks) of an ongoing placebo controlled trial (n=270) of this microbiota-based therapy derived from faecal samples delivered to patients via enema. Full data anticipated in 2nd half of 2020.


Biospace Inc.